Hemorrhagic events, safety and genetic factors among orally anticoagulated patients – Preliminary results

Aims: Over 60 000 patients receive per os anticoagulant treatment in Hungary. Attributable to the narrow therapeutic range and frequent hemorrhagic adverse events the use of coumarins represent elevated risk for gastrointestinal bleeding. Methods: Among patients arriving for prothrombin laboratory control were questionnaires fulfilled regarding clinical data and side effects of per os anticoagulant treatment. As polymorphisms in CYP2C9 and VKORC1 genes play an important role in coumarin pharmacogenetics, genetic testing was also performed. Results: A total of 59 adult patients (39 male, 20 female) were examined…